January 14, 2016 Horizon Pharma Completes Acquisition of Crealta Holdings LLC
December 11, 2015 Horizon Pharma plc to Acquire Crealta Holdings LLC
January 10, 2014 Crealta Completes Acquisition of Savient's Assets
January 8, 2013 Krystexxa® Receives Marketing Approval in EU
October 19, 2012 Savient Receives Positive Opinion for KRYSTEXXA Approval in EU
June 11, 2012 Mountain View Pharmaceuticals Announces Receipt of a European Patent on a Long-Acting Drug for MS
March 14, 2012 Mountain View Pharmaceuticals Announces Receipt of a U.S. Patent on Next-Generation PEGylation Technology (PharmaPEG)
November 30, 2010 Savient Announces Price and First Shipment of KRYSTEXXA
November 2, 2010 MVP receives US grant for research on PharmaPEG
September 14, 2010 FDA Approves KRYSTEXXA for Chronic Refractory Gout
March 30, 2010 Savient Announces PDUFA Date of 09-14-10
March 15, 2010 Savient Resubmits Biologics License Application for KRYSTEXXA
January 8, 2010 Savient Update on KRYSTEXXA BLA Filing
September 16. 2009 Savient provides update on FDA meeting
September 8, 2009 Savient press release re ACR Abstracts
August 2, 2009 Savient Receives Complete Response from FDA
June 16, 2009 FDA Arthritis Advisory Committee Recommends Approval of Pegloticase
May 29, 2009 Savient to Present Multiple Abstracts at 2009 EULAR Congress
January 28, 2009 Savient Announces FDA Advisory Panel
December 29, 2008 FDA Grants Priority Review to Pegloticase BLA Filing
October 31, 2008 Savient Submits Biologics License Application
October 27, 2008 Savient press release on ACR 10-27-08
September 22, 2008 Savient to Present Abstracts Related to Puricase® at ACR Meeting in October 2008
May 7, 2008 Savient Reports Favorable Interim Data from Uricase® Open Label Extension Study
April 21, 2008 Savient Provides Update on Puricase® BLA
February 4, 2008 Savient Reports Additional Positive Phase 3 Results for Puricase®
December 13, 2007 Savient Press Release - Successful Phase 3 Trials of Puricase®
October 16, 2007 Savient Completes Puricase® Phase 3 Study
March 6, 2007 Savient Completes Enrollment for Puricase® Phase 3 Study
August 4, 2006 Savient Completes Rosemont Sale
June 14, 2006 Savient Initiates Patient Dosing for Puricase® Phase 3 Study
May 3, 2006 Savient Receives FDA Final Approval for Puricase®
March 21, 2006 Savient and FDA Agree on Phase 3 Protocol SPA Puricase® (PEG-uricase) on Track to Enter Phase 3
November 14, 2005 Savient's Puricase® (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients with Treatment Resistant Gout
July 28, 2005 Savient Pharmaceuticals Meets with FDA for End-of-Phase 2 Review of Puricase®
June 29, 2005 Mountain View Pharmaceuticals Grants Worldwide License for a Long-Acting Protein
May 12, 2005 Savient Reports Positive Top-Line Results for Phase 2 Trial
May 4, 2005 Mountain View Pharmaceuticals Elects Raymond J. Land to Its Board of Directors
January 19, 2005 Mountain View Pharmaceuticals Grants Worldwide License for Long-Acting Multiple Sclerosis Drug
January 10, 2005 Savient Pharmaceuticals, Inc. Completes Patient Dosing in Phase II Clinical Trial of Puricase for Severe Gout
July 7, 2003 Savient Pharmaceuticals, Inc. Successfully Completes Phase I Clinical Study of Puricase® for Severe Gout
August 17, 1998 Bio-Technology General Acquires Rights to Technology for Important New Drug, PEG-Uricase, from Duke University and Mountain View Pharmaceuticals, Inc.